| 摘要: |
| 目的：观察银黄清肺胶囊治疗无症状及轻型/普通型新型冠状病毒（简称“新冠”）感染的临床疗效。方法：将 362 例新冠感染患者根据治疗方案的不同分为治疗组（242例）和对照组（120例）。对照组采用标准治疗方案治疗，治疗组在对照组治疗的基础上联合银黄清肺胶囊治疗。观察2组平均住院时间、平均核酸转阴时间、平均中医证候积分、重症/危重症转化情况，并比较临床疗效。结果：总有效率治疗组为97.52%（236/242），对照组为95.00%（114/120），2 组比较，差异有统计学意义（P<0.05）。治疗组的平均住院时间、平均核酸转阴时间均短于对照组（P<0.05）。治疗7 d后，2组中医证候积分治疗前后组内比较及治疗后组间比较，差异均有统计学意义（P<0.05）；治疗15 d后，2组中医证候积分均为0分。2组均未见重症/危重症转化情况。结论：与单用标准治疗方案相比，联合银黄清肺胶囊能更有效地缩短无症状及轻型/普通型新冠感染患者的住院时间、核酸转阴时间，改善中医症状。 |
| 关键词: 新型冠状病毒感染 无症状 轻型/普通型 银黄清肺胶囊 |
| DOI： |
|
|
| Clinical effect of Yinhuang Qingfei capsules in treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2 infection：An analysis of 242 cases |
| CHEN Feibao,ZHANG Changming,CHEN Chen |
| (Hunan Anbang Pharmaceutical Co.，Ltd.，Changsha 410300，Hunan，China;Shanghai Pudong Hospital，Shanghai 200120，China;Pudong New Area Pulmonary Hospital，Shanghai 200120，China) |
| Abstract: |
| Objective:To investigate the clinical effect of Yinhuang Qingfei capsules in the treatment of asymptomatic and mild/common severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.Methods：A total of 362 patients with SARS-CoV-2 infection were divided into treatment group with 242 patients and control group with 120 patients according to their treatment regimen.The patients in the control group were given standard treatment regimen，and those in the treatment group were given Yinhuang Qingfei capsules in addition to the treatment in the control group.The two groups were observed in terms of mean hospital stay，mean time to nucleic acid clearance，TCM syndrome score，and progression to severe/critical illness，and clinical outcome was compared between the two groups.Results：There was a significant difference in overall response rate between the treatment group and the control group ［97.52% (236/242) vs 95.00% (114/120)，P<0.05］.Compared with the control group，the treatment group had significantly shorter mean hospital stay and mean time to nucleic acid clearance (P<0.05).After 7 days of treatment，both groups had a significant change in TCM syndrome score，and there was a significant difference in TCM syndrome score between the two groups (P<0.05)；after 15 days of treatment，both groups had a TCM syndrome score of 0.Progression to severe/critical illness was not observed in either group.Conclusion：Compared with the standard treatment regimen alone，standard treatment regimen combined with Yinhuang Qingfei capsules can effectively shorten the length of hospital stay and the time to nucleic acid clearance and improve TCM symptoms in patients with asymptomatic and mild/common SARS-CoV-2 infection. |
| Key words: severe acute respiratory syndrome coronavirus 2 infection asymptomatic mild/common Yinhuang Qingfei capsules |
